Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Malaria | D008288 | EFO_0001068 | B54 | 4 | 4 | 1 | — | — | 9 |
Falciparum malaria | D016778 | EFO_0007444 | B50 | — | 3 | 1 | — | — | 4 |
Body weight | D001835 | EFO_0004338 | — | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Vivax malaria | D016780 | EFO_0007445 | B51 | — | 1 | — | — | — | 1 |
Drug common name | Ganaplacide |
INN | ganaplacide |
Description | Ganaplacide (development code KAF156) is a drug in development by Novartis for the purpose of treating malaria. It belongs to the class of the imidazolopiperazines. It has shown activity against the Plasmodium falciparum and Plasmodium vivax forms of the malaria parasite.
|
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC1(C)c2nc(-c3ccc(F)cc3)c(Nc3ccc(F)cc3)n2CCN1C(=O)CN |
PDB | — |
CAS-ID | 1261113-96-5 |
RxCUI | — |
ChEMBL ID | CHEMBL2058833 |
ChEBI ID | — |
PubChem CID | 49856296 |
DrugBank | — |
UNII ID | 85VMN9JU7A (ChemIDplus, GSRS) |